349 related articles for article (PubMed ID: 27187371)
1. Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy.
Passadouro M; Faneca H
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187371
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential.
Rawat M; Kadian K; Gupta Y; Kumar A; Chain PSG; Kovbasnjuk O; Kumar S; Parasher G
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31557962
[TBL] [Abstract][Full Text] [Related]
4. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
Steele CW; Oien KA; McKay CJ; Jamieson NB
Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
[TBL] [Abstract][Full Text] [Related]
5. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic Cancer Stem Cells and Therapeutic Approaches.
Ercan G; Karlitepe A; Ozpolat B
Anticancer Res; 2017 Jun; 37(6):2761-2775. PubMed ID: 28551612
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
8. A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma.
Papaconstantinou IG; Lykoudis PM; Gazouli M; Manta A; Polymeneas G; Voros D
Pancreas; 2012 Jul; 41(5):671-7. PubMed ID: 22695087
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs in pancreatic ductal adenocarcinoma: new diagnostic and therapeutic clues.
Seux M; Iovanna J; Dagorn JC; Dusetti NJ
Pancreatology; 2009; 9(1-2):66-72. PubMed ID: 19077456
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators.
Daoud AZ; Mulholland EJ; Cole G; McCarthy HO
BMC Cancer; 2019 Nov; 19(1):1130. PubMed ID: 31752758
[TBL] [Abstract][Full Text] [Related]
11. Targeting microRNAs in pancreatic cancer: microplayers in the big game.
Khan S; Ansarullah ; Kumar D; Jaggi M; Chauhan SC
Cancer Res; 2013 Nov; 73(22):6541-7. PubMed ID: 24204026
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs: novel diagnostic and therapeutic tools for pancreatic ductal adenocarcinoma?
Mardin WA; Mees ST
Ann Surg Oncol; 2009 Nov; 16(11):3183-9. PubMed ID: 19636633
[TBL] [Abstract][Full Text] [Related]
14. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
[TBL] [Abstract][Full Text] [Related]
15. Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer.
Gibori H; Eliyahu S; Krivitsky A; Ben-Shushan D; Epshtein Y; Tiram G; Blau R; Ofek P; Lee JS; Ruppin E; Landsman L; Barshack I; Golan T; Merquiol E; Blum G; Satchi-Fainaro R
Nat Commun; 2018 Jan; 9(1):16. PubMed ID: 29295989
[TBL] [Abstract][Full Text] [Related]
16. Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.
Taucher V; Mangge H; Haybaeck J
Cell Oncol (Dordr); 2016 Aug; 39(4):295-318. PubMed ID: 27060060
[TBL] [Abstract][Full Text] [Related]
17. The Promise of Gene Therapy for Pancreatic Cancer.
Vassaux G; Angelova A; Baril P; Midoux P; Rommelaere J; Cordelier P
Hum Gene Ther; 2016 Feb; 27(2):127-33. PubMed ID: 26603492
[TBL] [Abstract][Full Text] [Related]
18. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
Xie F; Li C; Zhang X; Peng W; Wen T
Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma.
Szafranska AE; Davison TS; John J; Cannon T; Sipos B; Maghnouj A; Labourier E; Hahn SA
Oncogene; 2007 Jun; 26(30):4442-52. PubMed ID: 17237814
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions.
du Rieu MC; Torrisani J; Selves J; Al Saati T; Souque A; Dufresne M; Tsongalis GJ; Suriawinata AA; Carrère N; Buscail L; Cordelier P
Clin Chem; 2010 Apr; 56(4):603-12. PubMed ID: 20093556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
